Desvenlafaxine in the treatment of major depressive disorder

References

• KesslerRCBerglundPDemlerOJinRMerikangasKRWaltersEELifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey ReplicationArch Gen Psychiatry200562659360215939837
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezADAlternative projections of mortality and disability by cause 1990–2020; Global Burden of Disease StudyLancet19973499064149815049167458
   PubMed Web of Science ®Google Scholar
• WHOThe global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html Accessed December 03, 2008.
   Google Scholar
• LopezADMathersCDEzzatiMJamisonDTMurrayCJGlobal and regional burden of disease and risk factors, 2001: systematic analysis of population health dataLancet200636795241747175716731270
   PubMed Web of Science ®Google Scholar
• PattenSBWangJLWilliamsJVDescriptive epidemiology of major depression in CanadaCan J Psychiatry2006512849016989107
   PubMed Web of Science ®Google Scholar
• MoussaviSChatterjiSVerdesETandonAPatelVUstunBDepression, chronic diseases, and decrements in health: results from the World Health SurveysLancet2007370959085185817826170
   PubMed Web of Science ®Google Scholar
• KennedySHLamRWEnhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychoticsBipolar Disord20035Suppl 2364714700011
   PubMed Web of Science ®Google Scholar
• TrivediMHRushAJWisniewskiSREvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry20061631284016390886
   PubMed Web of Science ®Google Scholar
• WardenDRushAJTrivediMHFavaMWisniewskiSRThe STAR*D Project results: a comprehensive review of findingsCurr Psychiatry Rep20079644945918221624
   PubMedGoogle Scholar
• ThaseMEEntsuahARRudolphRLRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitorsBr J Psychiatry200117823424111230034
   PubMed Web of Science ®Google Scholar
• NemeroffCBEntsuahRBenattiaIDemitrackMSloanDMThaseMEComprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIsBiol Psychiatry200863442443417888885
   PubMed Web of Science ®Google Scholar
• WeinmannSBeckerTKoestersMRe-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: metanalysisPsychopharmacology200819651152017955213
   PubMed Web of Science ®Google Scholar
• KennedySHAndersenHFLamRWEfficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisJ Psychiatry Neurosci200631212213116575428
   PubMed Web of Science ®Google Scholar
• ThaseMEAre SNRIs More Effective than SSRIs? A review of the current state of the controversyPsychopharmacol Bull2008412588518668017
   PubMedGoogle Scholar
• ThaseMEPritchettYLOssannaMJSwindleRWXuJDetkeMJEfficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorderJ Clin Psychopharmacol200727667267618004135
   PubMed Web of Science ®Google Scholar
• LamRWAndersenHFWadeAGEscitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trialsInt Clin Psychopharmacol200823418118718545055
   PubMed Web of Science ®Google Scholar
• KennedySHAndersenHFThaseMEEscitalopram in the treatment of major depressive disorder: meta-analysisCurr Med Res Opin20092516117519210149
   PubMed Web of Science ®Google Scholar
• DeecherDCAlfinitoPDLeventhalLCosmiSJohnstonGHMerchenthalerIAlleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent modelsEndocrinology200914831376138317122073
   PubMed Web of Science ®Google Scholar
• SperoffLGassMConstantineGOlivierSStudy 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trialObstet Gynecol20081111778718165395
   PubMed Web of Science ®Google Scholar
• WyrwichKWSprattDIGassMYuHBobulaJDIdentifying meaningful differences in vasomotor symptoms among menopausal womenMenopause200815469870518369313
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govAssessed October, 2008. Available from: http://www.clinicaltrials.gov/
   Google Scholar
• DeecherDCBeyerCEJohnstonGBrayJShahSAbou-GharbiaMDesvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitorJ Pharmacol Exp Ther2006318265766516675639
   PubMed Web of Science ®Google Scholar
• AlfinitoPDHuseltonCChenXDeecherDCPharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley ratsBrain Res200610981717816764833
   PubMed Web of Science ®Google Scholar
• VenuNSreekanthBRRamTDevarakondaSDesvenlafaxine succinate monohydrateActa Crystallogr C.2008645o29029218451490
   PubMedGoogle Scholar
• Wyeth PharmaceuticalsPristiq® Prescribing Information. Accessed October, 2008. Available from: http://www.wyeth.com/hcp/pristiq/prescribing-information
   Google Scholar
• BehrleJANicholsAIMcGrorySBRaibleDAn open-label, randomized, single dose, dose-proportionality study of oral doses of a sustained-release formulation of desvenlafaxine succinate in healthy subjects [abstract]Clin Pharmacol Ther2005772P82P82
   Web of Science ®Google Scholar
• ParksVPatatABehrleJParkerVDecoursJSafety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS-233 SR) in healthy subjects [abstract]Clin Pharmacol Ther2005772PI75
   Web of Science ®Google Scholar
• RichardsLSBehrleJANicholsRJFruncilloJPAn ascending multiple-dose study of the safety and pharmacokinetics of a sustained-release formulation of desvenlafaxine succinate in healthy subjects [abstract]Clin Pharmacol Ther2005772P84P84
   Web of Science ®Google Scholar
• PatronevaAConnollySFatatoPPedersenRJiangQPaulJAn Assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjectsDrug Metab Dispos2008362484249118809731
   PubMed Web of Science ®Google Scholar
• Baird-BellaireSPatatAAFauchouxNRehCNicholsAIBehrleAEffects of chronic hepatic impairment on the pharmacokinetics and safety of desvenlafaxine succinate extended release [abstract]Clin Pharmacol Ther2005792PI73
   Web of Science ®Google Scholar
• Septien-VelezLPitroskyBPadmanabhanSKGermainJMTourianKAA randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorderInt Clin Psychopharmacol200722633834717917552
   PubMed Web of Science ®Google Scholar
• DeMartinisNAYeungPPEntsuahRManleyALA double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorderJ Clin Psychiatry200768567768817503976
   PubMed Web of Science ®Google Scholar
• LiebowitzMRYeungPPEntsuahRA randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorderJ Clin Psychiatry200768111663167218052559
   PubMed Web of Science ®Google Scholar
• BoyerPMontgomerySLepolaUGermainJMBrisardCGangulyREfficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trialInt Clin Psychopharmacol200823524325318703933
   PubMed Web of Science ®Google Scholar
• LiebowitzMRManleyALPadmanabhanSKGangulyRTummalaRTourianKAEfficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorderCurr Med Res Opin20082471877189018507895
   PubMed Web of Science ®Google Scholar
• LiebermanDZMontgomerySATourianKAA pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorderInt Clin Psychopharmacol200823418819718545056
   PubMed Web of Science ®Google Scholar
• FeigerADTourianKARosasGRA placebo-controled efficacy and safety study of a flexible dose of desvenlafaxine succinate in outpatients with major depressive disorder. [Poster presentation]Presented at the 160th Annual Meeting of the American Psychiatry Association19–2452007San Diego, California, USA
   Google Scholar
• ClinicalStudyResults.orgAccessed October 2008. Available from: http://clinicalstudyresults.org
   Google Scholar
• ThaseMEKornsteinSGYeungPPEfficacy of desvenlafaxine succinate in the treatment of major depressive disorder: a pooled analysis of randomized, placebo controlled trials. [Poster presentation]Presented at the 20th Annual USPMG Congress1011–142007Orlando, Florida, USA
   Google Scholar
• LiebowitzMMontgomerySBoyerPEvaluation of the efficacy and safety of fixed doses of desvenlafaxine succinate at 50 mg and 100 mg in outpatients with major depressive disorder in 2 placebo-controlled trials. [Poster presentation]Presented at the American College of Neuropsychopharmacology Annual Meeting129–152007Boca Raton, Florida, USA
   Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• BechPGramLFDeinEJacobsenOVitgerJBolwigTGQuantitative rating of depressive statesActa Psychiatr Scand19755131611701136841
   PubMed Web of Science ®Google Scholar
• RickelsKMontgomerySATourianKAA multi-center, randomized, double-blind, placebo-controlled, parallel-group study of desvenlafaxine succinate for prevention of depressive relapse in adult outpatients with major depressive disorder [poster presentation]Presented at the 160th Annual Meeting of the American Psychiatric Association19–2452007San Diego, California, USA
   Google Scholar
• FergusonJTourianKARosasGRA 12-month open-label evaluation of long term safety and efficacy of desvenlafaxine succinate in outpatients with major depressive disorder [poster presentation]Presented at: The 160th Annual Meeting of the American Psychiatric Association19–2452007San Diego, California, USA
   Google Scholar
• RosenbaumJFFavaMHoogSLAscroftRCKrebsWBSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trialBiol Psychiatry199844277879646889
   PubMed Web of Science ®Google Scholar
• PatronevaAZitekBNinanPTAnalysis of weight change with short and longer term treatment with desvenlafaxine for major depressive disorder. [Poster presentation]Presented at the 20th Annual USPMG Congress1011–142007Orlando, Florida
   Google Scholar
• KamathJDeMartinisNHandrattaVEfficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. Future Neurol200724361
   Google Scholar
• LohoffFWRickelsKDesvenlafaxine succinate for the treatment of major depressive disorderExpert Opin Pharmacother20089122129213618671467
   PubMed Web of Science ®Google Scholar
• SopkoMAJrEhretMJGrgasMDesvenlafaxine: Another “me too” drug? (October) (CE)Ann Pharmacother2008421439144618698015
   PubMed Web of Science ®Google Scholar
• SprouleBAHazraMPollockBGDesvenlafaxine succinate for major depressive disorderDrugs Today (Barc)200844747548718806899
   PubMed Web of Science ®Google Scholar